Endocrinology, Vol 131, 1815-1820, Copyright © 1992 by Endocrine Society

ARTICLES

Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms

AM Rabuazzo, M Buscema, C Vinci, V Caltabiano, M Vetri, F Forte, R Vigneri and F Purrello
Institute of Internal Medicine, Metabolism, and Endocrinology, University of Catania Medical School, Italy.

Insulin secretion was studied in rat pancreatic islets after 24-h exposure to various glyburide or tolbutamide concentrations. Glucose- induced insulin release was significantly (P < 0.05) reduced in islets cultured with 0.1 microM glyburide or 100 microM tolbutamide (2098 +/- 187, 832 +/- 93, and 989 +/- 88 pg/islet.h in control, glyburide- exposed, and tolbutamide-exposed islets, respectively). When glyburide- treated islets were stimulated with glyburide or tolbutamide, insulin release was also impaired compared to that in control islets (P < 0.05). In contrast, tolbutamide-exposed islets showed an impaired response to tolbutamide, but a normal response to glyburide. To investigate the mechanism of the sulfonylurea-induced impairment of insulin secretion, we measured insulin release and Rb+ efflux (a marker of the K+ channel activity) in a perifusion system and islet Ca2+ uptake under static conditions. Insulin release in response to 16.7 mM glucose increased in control islets from 9.4 +/- 1.1 to 131 +/- 19 pg/islet.min (first phase secretion peak). Simultaneously, the fractional 86Rb+ efflux declined from 0.015 +/- 0.002% to 0.006 +/- 0.001% (change in decrement, -63.5%). Glucose-induced insulin release in glyburide- and tolbutamide-treated islets was significantly reduced (first phase peak, 22.1 +/- 5 and 39.7 +/- 8 pg/islet.min, respectively; P < 0.05), and the fractional 86Rb+ efflux decrement was - 21 +/- 6% for glyburide (P < 0.005 vs. control islets) and -65 +/- 4% (not different from control) for tolbutamide. When glyburide- or tolbutamide-exposed islets were stimulated with the corresponding sulfonylurea, insulin release was impaired compared to that in control islets (P < 0.05), but, again, 86Rb+ efflux was impaired (P < 0.05) only in glyburide-exposed islets. When 45Ca2+ uptake was studied, the increase in glucose concentration from 2.8 to 16.7 mM increased calcium uptake in control islets from 1.76 +/- 0.58 to 7.27 +/- 1.36 pmol/islet.2 min (n = 4). Preexposure to 0.1 microM glyburide did not change calcium uptake at a glucose concentration of 2.8 mM (1.44 +/- 0.45 pmol/islet.2 min) but significantly reduced calcium uptake stimulated by 16.7 mM glucose (3.21 +/- 0.35 pmol/islet.2 min; n = 4; P < 0.005 compared to control islets). In contrast, preexposure to 100 microM tolbutamide did not change either basal or glucose-stimulated calcium uptake (1.44 +/- 0.45 and 6.90 +/- 0.81 pmol/islet.2 min, respectively; n = 4). These data show that in vitro chronic exposure of pancreatic islets to the sulfonylureas glyburide and tolbutamide impairs their ability to respond to a subsequent glucose or sulfonylurea stimulation.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				I. Rustenbeck, A. Wienbergen, C. Bleck, and A. Jorns Desensitization of Insulin Secretion by Depolarizing Insulin Secretagogues Diabetes, December 1, 2004; 53(suppl_3): S140 - S150. [Abstract] [Full Text] [PDF]

				M. Anello, V. Ucciardello, S. Piro, G. Patane, L. Frittitta, V. Calabrese, A. M. Giuffrida Stella, R. Vigneri, F. Purrello, and A. M. Rabuazzo Chronic exposure to high leucine impairs glucose-induced insulin release by lowering the ATP-to-ADP ratio Am J Physiol Endocrinol Metab, November 1, 2001; 281(5): E1082 - E1087. [Abstract] [Full Text] [PDF]

				S. L.F. Chan, M. Mourtada, and N. G. Morgan Characterization of a KATP Channel--Independent Pathway Involved in Potentiation of Insulin Secretion by Efaroxan Diabetes, February 1, 2001; 50(2): 340 - 347. [Abstract] [Full Text]